Aeglea BioTherapeutics Inc

Aeglea BioTherapeutics Inc

AGLE - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.02B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Aeglea BioTherapeutics IncAeglea BioTherapeutics Inc-49.5--16%--
$12.29

Current Fair Value

2.4% upside

Undervalued by 2.4% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.02 Billion
Enterprise Value$855.59 Million
Earnings per Share$-1.98
Beta2.57
Outstanding Shares84,729,435

Return

Return on Equity-16.25%ROE
Return on Assets-15.25%
Return on Invested Capital-18.14%

Valuation & Multiples

P/E Ratio-49.52P/E Ratio
PEG3516.73PEG
Price to Sales-Price to Sales
Price to Book Ratio1.0Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT0.56
Enterprise Value to Net Income-5
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 4, 2026
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Aeglea BioTherapeutics Inc

Aeglea BioTherapeutics Insider Information FAQ

In the latest 13F quarter on Stockcircle, 2 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.